Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynerba Pharmaceuticals Inc told investors that an article in the Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEVE study as positive. This is an open label study assessing the "safety and efficacy" of Zygel (ZYN002) as a transdermal gel for children and adolescents with developmental and epileptic encephalopathy (DEE).

Zynerba Pharmaceuticals says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journal

Zynerba Pharmaceuticals Inc told investors that an article in the  Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEVE study as positive. This is an open label study assessing the "safety and efficacy" of Zygel (ZYN002) as a transdermal gel for children and adolescents with developmental and epileptic encephalopathy (DEE).

Zynerba Pharmaceuticals Inc says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journal

DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

In a note to clients on August 20, Canaccord Genuity analysts reiterated their ‘Buy' rating and $9 target price on shares of Zynerba Pharmaceuticals Inc, saying “ZYNE stock presents a potentially significant opportunity for patient and risk-tolerant investors.” Zynerba announced recently that it reached an agreement with the US Food and Drug Administration (FDA) on a path forward for Zygel (synthetic transdermal cannabidiol gel) in Fragile X syndrome (FXS).

Zynerba Pharmaceuticals stock “presents a potentially significant opportunity for patient investors,” says Canaccord Genuity

Agrify

Anebulo Pharmaceuticals

Clever Leaves Holdings

Greenlane Holdings

Hydrofarm Holdings Group

Jazz Pharmaceuticals

Akerna Corp

Merida Merger

Scotts Miracle-Gro

Turning Point Brands

Urban-gro

Village Farms International

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

A Week's Worth of Actionable Cannabis Stock News

Zynerba Pharmaceuticals Inc has posted second-quarter results with ample cash on hand, which gives the company a long runway to run pivotal trials of its flagship product Zygel (ZYN002), a patent-protected CBD skin gel, which is being developed to treat a slew of rare neuropsychiatric disorders, including Fragile X syndrome (FXS) and developmental and epileptic encephalopathies (DEE) programs.  The Devon, Pennsylvania-based company had $85.8 million in cash and equivalents as of June 30, 2021, compared to $59.2 million at the end of December 2020.

Zynerba Pharmaceuticals flush with $85.8M in 2Q to fund pivotal trials of its flagship Zygel CBD gel

DEVON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update.

Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41st Annual Growth Conference being held virtually on Wednesday, August 11, 2021 at 1:30 p.m. ET.

Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

OrganiGram Holdings Inc.

SNDL Inc.

Which marijuana penny stocks are investors watching after Tilray's spike today? The post Why Weed Penny Stocks Are Up Today & 3 to Watch as Tilray Skyrockets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Weed Penny Stocks Are Up Today & 3 to Watch as Tilray Skyrockets

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m. ET.

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.

Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies

DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual M

Arena Pharmaceuticals

Canopy Growth

Cardiff Oncology

Cronos Group

GrowGeneration Corp

Hawaiian Electric Industries

Innovative Industrial Properties

Neptune Wellness Solutions Inc.

22nd Century Group

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Smoked! How the Hottest Cannabis Stocks Fared This Week

–  46.4% of shares voted, quorum not established to hold annual meeting –

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC, which will be held virtually from June 10-13, 2021. A copy of the poster will be made available on the Zynerba corporate website at the time of presentation at http://zynerba.com/publications/. Additional meeting information can be found on the SLEEP website at https://www.sleepmeeting.org/.

Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. – 11:00 a.m. ET in poster session II at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021. A copy of the poster will be made available on the Zynerba corporate website at the time of presentation at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET.

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Aurora Cannabis

Applied DNA Sciences

Cara Therapeutics

Corbus Pharmaceuticals Holdings

Flora Growth Corp

HEXO Corp

Here Are the Cannabis Stocks That Caught Fire This Week

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights

Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024

Akebia Therapeutics

Hertz

These Reddit penny stocks are climbing today; are they worth adding to your watchlist? The post These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?

These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of $93.1 million on hand at the end of the first quarter.  In a business update for the three months ended March 31, the company reported that cash on hand increased 57% year-over-year from $59.2 million at the end of the first quarter last year.

Zynerba says its fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patients

– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 –

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).  The trial, which will be called RECONNECT (A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome), is designed to evaluate the efficacy and safety of Zygel in children and adolescents with FXS.

Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting.  Both posters will be made available on the Zynerba corporate website.

Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting

News for Zynerba Pharmaceuticals Stock (ZYNE)